487 related articles for article (PubMed ID: 30114330)
1. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
[TBL] [Abstract][Full Text] [Related]
2. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
5. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
6. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
Ivey GD; Shoucair S; Delitto DJ; Habib JR; Kinny-Köster B; Shubert CR; Lafaro KJ; Cameron JL; Burns WR; Burkhart RA; Thompson EL; Narang A; Zheng L; Wolfgang CL; He J
World J Surg; 2022 Nov; 46(11):2751-2759. PubMed ID: 35861852
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP.
Krell RW; McNeil LR; Yanala UR; Are C; Reames BN
Ann Surg Oncol; 2021 Jul; 28(7):3810-3822. PubMed ID: 33386542
[TBL] [Abstract][Full Text] [Related]
8. Utilization of chemoradiation therapy provides strongest protective effect for avoidance of postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis.
Mangieri CW; Strode MA; Moaven O; Clark CJ; Shen P
J Surg Oncol; 2020 Dec; 122(8):1604-1611. PubMed ID: 32935353
[TBL] [Abstract][Full Text] [Related]
9. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach.
Hyman DW; Almerey T; Mujkanovic A; Hammons I; Tice M; Stauffer JA
Am Surg; 2022 Aug; 88(8):1868-1874. PubMed ID: 35465681
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
11. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
13. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
14. Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes.
Jung JH; Yoon SK; Yoon SJ; Shin SH; Han IW; Heo JS
Anticancer Res; 2021 Nov; 41(11):5703-5712. PubMed ID: 34732443
[TBL] [Abstract][Full Text] [Related]
15. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis.
Davis CH; Augustinus S; de Graaf N; Wellner UF; Johansen K; Andersson B; Beane JD; Björnsson B; Busch OR; Gleeson EM; van Santvoort HC; Tingstedt B; Williamsson C; Keck T; Besselink MG; Koerkamp BG; Pitt HA;
J Am Coll Surg; 2024 Apr; 238(4):613-621. PubMed ID: 38224148
[TBL] [Abstract][Full Text] [Related]
16. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
Sternby H; Andersson B
Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
[TBL] [Abstract][Full Text] [Related]
18. Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma.
Mitsakos AT; Dennis SO; Parikh AA; Snyder RA
J Surg Oncol; 2021 Mar; 123(4):970-977. PubMed ID: 33497474
[TBL] [Abstract][Full Text] [Related]
19. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
20. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]